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BACKGROUND: Individualised breast cancer risk prediction models may be key for planning risk-based screening approaches. Our
aim was to conduct a systematic review and quality assessment of these models addressed to women in the general population.
METHODS: We followed the Cochrane Collaboration methods searching in Medline, EMBASE and The Cochrane Library databases
up to February 2018. We included studies reporting a model to estimate the individualised risk of breast cancer in women in the
general population. Study quality was assessed by two independent reviewers. Results are narratively summarised.
RESULTS: We included 24 studies out of the 2976 citations initially retrieved. Twenty studies were based on four models, the Breast
Cancer Risk Assessment Tool (BCRAT), the Breast Cancer Surveillance Consortium (BCSC), the Rosner & Colditz model, and the
International Breast Cancer Intervention Study (IBIS), whereas four studies addressed other original models. Four of the studies
included genetic information. The quality of the studies was moderate with some limitations in the discriminative power and data
inputs. A maximum AUROC value of 0.71 was reported in the study conducted in a screening context.
CONCLUSION: Individualised risk prediction models are promising tools for implementing risk-based screening policies. However,
it is a challenge to recommend any of them since they need further improvement in their quality and discriminatory capacity.
British Journal of Cancer (2019) 121:76–85; https://doi.org/10.1038/s41416-019-0476-8
BACKGROUND
Mammography screening has been associated with a reduction in
breast cancer mortality and therefore organised breast cancer
screening programmes using mammography have been well
established worldwide.1–4 Although there is not a single consensus,
current screening programmes generally recommend biennial or
triennial screening in Europe and annual or biennial screening in
the US with variations in the recommended targeted age.2–5 These
recommendations usually consider age as the sole risk factor
leading women to be invited for screening from age 40–50 until
age 70–74, depending on the programmes.
The likelihood that a woman will beneﬁt from screening
mammography depends on her risk for developing clinically
signiﬁcant breast cancer in her lifetime. Taking individual risk
factors beyond age into account should enable the classiﬁcation
of women into groups at varying risk of breast cancer.
Personalised risk-based screening going beyond the current
‘one-size ﬁts all' recommendation may increase the effectiveness
and beneﬁt-harm balance of breast cancer screening. Individua-
lised risk prediction models for breast cancer are a key element to
develop risk-based screening approaches since they are designed
to quantify the risk that can predict whether an individual woman
would develop breast cancer in a deﬁned period.6
A number of risk prediction models that include classical
risk factors are commonly used in clinical contexts.7 However,
organised screening programmes do not use these models
routinely. One reason for not including these models in screening
context is the high uncertainty with regards to its applicability in
screening settings. Also, the emergence of new risk prediction
factors such as the expression of single nucleotide polymorphisms
(SNPs) needs to be appropriately summarised before recommend-
ing one of the models into screening practice.
Like any other source of information, risk prediction models
have limitations that should be evaluated before using them. A
rigorous risk of bias assessment of the existing individualised risk
models is needed to clarify the overall quality and applicability of
each model. Therefore, the aim of this systematic review is to
update the existing evidence, conduct a critical appraisal and risk
of bias assessment and summarise the results of the individualised
risk models which are used to estimate the risk of breast cancer in
women in the general population.
METHODS
Data sources and searches
We performed a systematic review of the literature following the
standard Cochrane Collaboration methods8 and adhering to the
PRISMA statement reporting recommendations.9 A predetermined
review protocol was registered (CRD42018089842) in the PROS-
PERO database (date of registration 1 March 2018). The Patient,
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Intervention, Comparison, Outcomes (PICO) question of this
systematic review is the following: Should individualised breast
cancer risk prediction models vs. no risk prediction models be
used to develop risk-based screening approaches for women in
the general population?
We retrieved relevant literature by using a combination of
controlled vocabulary and keyword search terms in the following
databases: (i) Medline (accessed through PubMed); (ii) The
Cochrane Library; and (iii) EMBASE (accessed through Ovid).
Terms related to breast cancer recurrence were excluded in order
to avoid retrieving citations out of the scope of this systematic
review. We adapted the search algorithms to the requirements of
each database and used validated ﬁlters to retrieve systematic
reviews and primary studies as needed. We reviewed references of
included studies that could potentially fulﬁl our eligibility criteria.
The detailed search strategy is reported in Supplementary table 1.
We searched primary studies of individualised breast cancer
risk models searching each database from its inception up to
February 2018.
Study selection
Eligible studies were those published in English that reported a
model to estimate the individualised risk of breast cancer in
women in the general population. We included models that
assessed more than one risk factor and reported the quantitative
characteristics of the risk prediction model. If multiple publications
were based on the same individualised risk model, the most
extensive report of the model in terms of risk factors reported was
chosen. We excluded external validation studies that replicated
previous models without adding any additional information such
as a new design for collecting the inputs data, modiﬁcations on
the risk factors or the risk model method.
Articles identiﬁed from the search were loaded into EndNote
X7.7.1 for Windows (2008, Version 12.0.4) and duplicates were
removed.
Data extraction and quality assessment
One reviewer screened the search results based on title and
abstract, and a second reviewer performed a quality check of the
study screening by reviewing 20% of the references. Two
reviewers independently conﬁrmed eligibility based on the full
text of the relevant articles. In case of disagreement between
researchers, the inclusion of studies was determined by con-
sensus. We reported the result of this process with a PRISMA
ﬂowchart (Fig. 1).
We used a predeﬁned form to extract the following information
from included studies: author, publication date, country, study
design, the name of the model if available, sample characteristics,
sample size, type of breast cancer, the method of analysis, and
validation of the model. Data abstraction was conducted by one
reviewer and checked by another.
Two reviewers carried out the assessment of the risk of bias
independently and ﬁnal quality assessment was based on
consensus. We used the ISPOR-AMCP-NPC Questionnaire10 to
assess the relevance and credibility of each risk prediction study
and the following sources of limitations: (i) internal and external
validation; (ii) bias due to the study design for risk estimates; (iii)
limitations in data inputs; (iv) appropriateness of the model
analysis; (v) reporting bias; (vi) interpretation bias; and (vii) conﬂict
of interest. The risk of bias for each domain was rated as low, high
or unclear. For systematic reviews we used the AMSTAR 2 critical
appraisal tool.11
Data synthesis and analysis
We evaluated the model validation by assessing both the
discriminative power and the calibration accuracy estimated for
the women in the general population. When available in the
included publication, we extracted the area under the receiver
operating characteristic curve (AUROC), the net reclassiﬁcation
index (NRI) and the expected observed (E/O) ratio. The NRI was
not included in the tables because it was only reported in 2 out of
24 articles. The characteristics of the included models and the risk
prediction outcomes reported preclude the possibility to pool
data across studies. Therefore, a narrative synthesis has been
conducted. Key study characteristics, validation and accuracy of
individual risk models, and methodological quality are described
in tables and summarised in a narrative manner. Results are
presented according to the original model that they reported.
RESULTS
Study inclusion
The database searches for primary studies retrieved 2974 citations,
of which 79 were considered potentially relevant. These 79 studies
were screened in full text. We found a systematic review of
Anothaisintawee et al.,7 which we used as a source of primary
studies. In addition, two studies were included after a manual
inspection of papers’ references.12,13 After the full text was
checked, 24 studies12–35 met the inclusion criteria and were
considered in the evidence synthesis. Details about study
inclusion with reasons for exclusion are described in the ﬂow-
chart (Fig. 1), and a list of references to excluded studies is
provided in Supplementary table 2.
MEDLINE
(N = 2032)
EMBASE
(N = 1718)
Records identified through
database searching
(N = 3966)
Duplicated records
(N = 922)
Excluded records
(N = 2895)
Records screened by title
and abstract (N = 2974)
Full text articles assessed for
eligibility (N = 79)
Full text articles excluded
(N = 57)
Additional records
identified through other
sources (N = 2)
Studies included in the
synthesis (N = 24)
(Did not assess a new risk prediction model, N = 23)
(Secondary publication, N = 18)
(Wrong setting, population, N = 8)
(Not risk prediction model, N = 6)
(Wrong study outcomes, N = 2)
The Cochrane library
(N = 216)
Fig. 1 PRISMA ﬂowchart
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Characteristics of the included studies
The included studies can be grouped according to the risk
model that they reported, the Breast Cancer Risk Assessment
Tool (BCRAT), the Breast Cancer Surveillance Consortium (BCSC),
the Rosner & Colditz model, the International Breast
Cancer Intervention Study (IBIS), and other original models.
The study by Zhang et al.13 is included in two of the
groups (BCRAT and Rosner & Colditz models) because it
provides information of both models and presents its results
separately. A brief summary of the 24 included studies is
presented in Table 1 and the extended characteristics in
Supplementary table 3.
a. Breast Cancer Risk Assessment Tool ‘BCRAT’ model. This
model was ﬁrst published in the United States in 1989
assessing age, family history of breast cancer, age at ﬁrst
birth, menarche, and previous biopsies as risk factors for
predicting individualised breast cancer risk.22 After this ﬁrst
publication, eight studies were identiﬁed that were based
on BRCAT model but modiﬁed the data collection design,
assessed additional risk factors or changed the statistical
method. In addition to the ﬁve risk factors proposed in 1989,
other variables such as body mass index (BMI), weight,
hormone replacement therapy (HRT), alcohol consumption,
physical activity, diet, breast density, atypical hyperplasia,
breast inﬂammatory disease, parity, a polygenic risk score or
hormones information have been included in updated
versions (Table 1).13,14,16,17,20,23,25,26,30
b. Breast Cancer Surveillance Consortium ‘BCSC’ model. One
relevant variation of the BCRAT model opens the path to
the emergence of the BCSC model ﬁrst published by Tice
et al. in 2008 in the United States.31 In this study, Tice et al.
used data from a cohort to create an individualised risk
prediction model that combines age, family history,
previous biopsies, breast density, and ethnicity. The BCSC
model has been further evaluated by other authors12,24,29,32
and it currently includes previous benign breast diseases
and polygenetic risk score using SNPs as risk factors
(Table 1).
c. Rosner & Colditz model. Parallel to the BCSC model, another
model based on the ‘Nurses' Health Study’ cohort devel-
oped by Rosner & Colditz in 1996 was also developed in the
United States. This model currently includes 11 risk factors:
age, menarche, menopause, age at ﬁrst birth, age at
subsequent births, previous benign breast disease, HRT,
family history, weight, BMI, alcohol consumption, and
oestradiol levels.18,19,27,28 In the same way as in the BCRAT,
Zhang et al.13 analysed this model adding breast density, a
polygenic risk score and endogenous hormones as risk
factors.
d. International Breast Cancer Intervention Study ‘IBIS’ model.
The IBIS model33 includes genetic information adding the
BRCA genes and a hypothetical susceptibility gene.
e. Other models. Four studies reporting different models were
also identiﬁed.15,21,34,35 Apart from the above-mentioned
risk factors, the models also assessed other variables such as
abortion, breastfeeding, height, and previous mammogra-
phy results. Particularly relevant is the Eriksson model21
since it was the only one targeted to the screening
population. In this study, the authors included risk factors
that were available at mammography screening examina-
tion: age, BMI, HRT, family history, menopause, breast
density, and presence of microcalciﬁcations and/or masses
in the screen-mammogram.
Discriminatory accuracy
Fifteen out of the 24 studies reported the discriminatory accuracy
as the AUROC (Table 1 and Fig. 2).
a. BCRAT model. The ﬁrst BCRAT model publication did not
report the AUROC, however, later publications of this model
reported a range that varied from 0.56 to 0.68. The three
publications that included the original risk factors, age,
family history of breast cancer, age at ﬁrst birth, menarche,
and previous biopsies, reported low AUROC values, 0.56 to
0.62.14,20,23 Similarly, the AUROC reported by Boyle et al.16
and Matsuno et al.25 were 0.60 and 0.61, although these
authors added BMI, HRT, alcohol, physical activity and diet,
and ethnicity into the model. Zhang et al.13 with the new
variables reach an AUROC of 0.65 and Tice et al.30 reported
in 2005 a higher AUROC value of 0.68 which was obtained
just adding breast density to the original ﬁve risk factors
(Table 1). Zhang et al.13 also reported the NRI to validate
that his model improved the previous ones with a
result of 8%.
b. BCSC model. The published value of the AUROC for the
BCSC model was moderate, ranging from 0.64 to 0.69. Tice
et al. included age, family history, previous biopsies, breast
density reported by the Breast Imaging Reporting and Data
System (BI-RADS), and ethnicity into the model in 2008 and
obtained a value of 0.66 for the AUROC.31 Instead of
BI-RADS, Kerlikowske et al. assessed changes in breast
density obtaining a similar result, 0.64.24 Using previous
benign breast disease, Tice et al. obtained a slightly higher
AUROC value of 0.67 in 2015.32 More recently, in 2015 and
2016, Vachon et al.12 added to the model a polygenic risk
score and Shieh et al.29 a combination between a
polygenic risk score and BMI reporting a value of 0.69
and 0.65 for the AUROC respectively (Table 1). Vachon
et al.12 also demonstrated the improvement of discrimina-
tory accuracy estimating the NRI with a positive result
of 11%.
c. Rosner & Colditz model. The discriminatory accuracy of this
model varied from 0.61 to 0.68. The authors assessed age,
family history, age at ﬁrst birth, menarche, BMI, benign
breast disease, menopause, HRT, age at subsequent births,
alcohol, and weight. They obtained an AUROC of 0.64 and
0.61 for ER+ /PR+ and ER-/PR- tumours, respectively.19
The addition of oestradiol levels to the model was tested
by Rosner et al. who obtained a 0.65 AUROC value in
2008.28 Finally the addition of a polygenic risk score,
mammographic density and endogenous hormones by
Zhang et al.13 reached a 0.68 AUROC value (Table 1) and
obtained an improvement of the discriminative accuracy
also reﬂected in a NRI of a 9.5%.
d. IBIS model. The IBIS model original paper33 does not
include any validation and does not present the AUROC.
Nevertheless, it has been externally validated showing an
AUROC of 0.57 which increases to 0.61 when adding
mammographic density.36
e. Other models. Overall, the AUROC values of these models
were not higher than those shown by the above-
mentioned models, varying from 0.62 to 0.64, although
they included a large number of risk factors. However, the
model reported by Eriksson et al.21 did show an AUROC of
0.71 that was the highest AUROC value identiﬁed in this
systematic review (Table 1). This model, in addition, is the
only one that estimates a 2-year risk, while the rest of
models estimate the risk at a longer time horizon. This
could explain the difference in AUROC values since it
becomes more difﬁcult to predict risk as the time horizon
increases.
Calibration accuracy
Nine out of the 24 studies reported the calibration accuracy as the
E/O ratio (Table 1).
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a. BCRAT model. Of the 10 studies derived of the
BCRAT model, ﬁve reported the calibration accuracy.
Banegas et al.14 presented heterogeneous results depend-
ing on the provenance of the population, reporting an E/O
ratio of 0.93 for US-born and 1.52 for foreign-born women.
Although Matsuno et al.25 added new variables to the
original BCRAT model, the E/O ratio was 0.85, which was
the lowest of the group, whereas the other studies
published E/O ratios that varied from 0.93 to 1.0316,20,23
(Table 1).
b. BCSC model. Tice et al. published in 2008 a value of 1.03
for the E/O ratio when looking at 5-year risk.31 Using
previous benign breast disease, they obtained a similar
result in 2015, with an E/O ratio of 1.04 for 5-year risk
and 1.05 for 10-year risk.32 When Kerlikowske et al.
assessed changes in breast density the ratio decreased
obtaining a 0.98 for 5-year risk and 0.95 for 10-year risk.24
The studies of Vachon et al. and Shieh et al. did not
present validation regarding the calibration accuracy of
the model (Table 1).
c. Rosner & Colditz model. Of the ﬁve studies based on the
Rosner & Colditz model,13,18,19,27,28 none of them reported
calibration accuracy statistics of their models for the
women in the general population.
d. IBIS model. The IBIS model original paper33 does not
report any calibration statistic. Nevertheless, other articles
have validated it showing an E/O ratio of 1.67.36
e. Other models. The study Barlow et al.15 was the only one
that reported calibration accuracy and presented the
closest E/O ratio to one of all the studies included in this
review taking values of 1.00 and 1.01 for pre and post-
menopausal status respectively (Table 1).
Quality assessment
The quality of the included studies was moderate due to
some limitations in the discriminative power, study design, and
data inputs. The studies did not show important limitations with
regards to the validation, appropriateness of the model analysis,
reporting or interpretation of the results (Fig. 3). A summary of the
risk of bias assessment per each source of limitation is presented
here and the detailed appraisal and judgements in Supplementary
table 4.
Internal and external validation
Ten studies14–17,20,23,25,26,30,31 validated their models by compar-
ing the results with those published by Gail et al.,22 three
studies24,29,32 compared with Tice et al.,31 one21 compared with
both Gail et al.22 and Tyrer et al.,33 one13 compared with both
Gail et al.22 and the results of a Rosner & Colditz model external
validation37 and three studies did not report the model
validation in the primary articles.19,22,34 Six studies assessed
internal validation with a sample of the population that
generated data for the model,15,16,24,29,31,32 and four with an
external population.14,20,23,25 Despite not having reported the
external validation in the primary articles, the Rosner & Colditz
model18,19,27,28 reported external validation in a subsequent
article mentioned before.37 Nine studies used the expected/
observed event ratio to measure the calibration accuracy of the
model.14–16,20,23–25,29,31
Bias due to the study design
Thirteen studies used a case-control design to obtain breast
cancer risk estimates,12–14,16,17,20–23,25,26,29,34 ﬁve studies used
prospective cohorts,15,18,19,27,28 and four models used retro-
spective cohorts.24,30–32 The study of Wang et al.35 and the study
of Tyrer et al.33 used risk estimates obtained from a systematic
review of the literature.T
ab
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Limitations of data inputs
Sixteen studies obtained most of the input parameters from self-
reported questionnaires.13–20,22,23,25–28,30,34 The study of Matsuno
et al.25 also imputed ethnicity for women with missing data.
Appropriateness of the model analysis
Thirteen studies12–17,20,22,23,25,26,29,34 used logistic regression to
estimate the risk of having breast cancer according to the
assessed risk factors, ﬁve used proportional hazard Cox
models,21,24,30–32 four used Poisson regression models,18,19,27,28
and the other two studies used risk estimates obtained from a
systematic review of the literature.33,35
Reporting bias
Twenty one studies reported all relevant and necessary informa-
tion for the model creation.12–23,25–29,31,33–35 Conversely, a critical
lack of information was found in the other three studies.24,30,32
DISCUSSION
Summary of main results
This systematic review included 24 studies that aimed to estimate
the individual risk of developing breast cancer in women in the
general population. Twenty studies were based on four speciﬁc
risk models (the BCRAT, the BCSC, the Rosner & Colditz and the
IBIS model),16–20,22–33 whereas four studies used other original
models.15,21,34,35 The most extensively used were the BCRAT, IBIS
and the BCSC models. The number of risk factors included in the
models ranged from ﬁve to 18. Other than age, which was the
only risk factor present in all models, the BCRAT model also
included family history, age at ﬁrst birth, menarche, and previous
biopsies. Breast density, benign breast disease, and polygenetic
score were predominant in the BCSC model. Although during the
last decade the models have shown improvements in their
discriminatory accuracy, it remains at best moderate with a
maximum AUROC value of 0.71 reported by Eriksson et al.21 The
calibration accuracy was very heterogeneous ranging from 0.85 to
1.52. Furthermore, the quality of the studies was not high due to
limitations in the discriminative accuracy, study design, and data
inputs.
Agreements and disagreements with other reviews
In this systematic review, we found that the number of
individualised breast cancer risk prediction models has increased
steadily over the past three decades. This ﬁnding is in agreement
with the narrative overview published by Cintolo-Gonzalez et al. in
2017,38 and it updates the results of a previous systematic review
published by Anothaisintawee et al. in 2012.7 In contrast to these
reviews, however, our aim was to provide innovative information
regarding the quality of the identiﬁed prediction models. Thus, we
have identiﬁed and rigorously analysed the strengths and
limitations of 24 individualised models in order to adjust our
conclusions to the quality of the evidence.
We have identiﬁed two new trends with regards to the use and
development of the models, which are the increased use of the
BCSC model and the inclusion of common genetic variation in the
prediction models. As compared to the information published in
the review of Anothaisintawee et al.,7 we found that in contrast to
the BCRAT and Rosner & Colditz models that were the most
frequently cited models up to 20107 the BCSC model has
concentrated the attention of several authors during the last ﬁve
years, although its discriminatory accuracy has not dramatically
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improved. Second, none of the models in the review of
Anothaisintawee et al.7 included genetic information as a risk
factor. By contrast, we have identiﬁed four models including
genetic information: the IBIS model33 that includes genetic
phenotype in their updated version, the BCSC model that includes
a polygenetic score in both 201512 and 201629 publications, as
well as the article by Zhang et al. that added a polygenic risk score
to both the BCRAT and the Rosner & Colditz models.13
Most of the included studies reported the AUROC to determine
the probability that a randomly chosen woman with disease
would be correctly categorised as higher risk compared to a
randomly chosen woman without disease. The discriminatory
accuracy estimate does not express whether the model is more or
less accurate in predicting the risk of speciﬁc individuals but
measures the capacity of the model to determine which women
are at higher/lower risk for developing breast cancer. Thus, both
calibration accuracy and discriminatory accuracy should be
assessed. Contrary to what is expected, we found that authors
reported the E/O ratio only in less than half of the included
studies. In addition to the AUROC value, the studies of Zhang et al.
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and Vachon et al.12,13 also reported an improvement in the net
reclassiﬁcation index (NRI) of the BCRAT, and Rosner & Colditz
models, as well as in the BCSC model, respectively.
Overall, the information provided by the AUROC and the E/O
ratio was consistent suggesting that the included models have
moderate discriminatory accuracy and calibration accuracy when
applied to the women in the general population. Nevertheless, it
must be taken into account that despite the great importance of
validation in terms of AUROC and E/O ratio, the presence of low
values of AUROC or clearly different from 1 values of the E/O ratio
does not mean that these models are useless. On the contrary,
models are clinically useful even with moderate AUROC since they
can reclassify individuals at the extremes of risk.39 Thus, the
verdict on risk models should not be based solely on these
estimators. Instead, they need to be prospectively evaluated in
clinical trials. In fact, there are currently two very large randomised
trials assessing risk-based screening strategies. Both of them are
using individualised models. Both the IBIS and the BCSC models
are being tested in the European trial MyPeBS (My Personalised
Breast Screening).40 Also, the BCSC model is being tested in the US
WISDOM trial (Women Informed to Screen Depending On
Measures of risk).41
Applicability and completeness of evidence
The distribution of risk factors in such different populations may
affect the applicability of the models to different contexts. The fact
that different subtypes of breast cancer may have different
genetic markers is widely accepted.42 These differences, the
nature of breast cancer itself and its low incidence may condition
a low discriminatory accuracy of a model. In other words, in the
general population, there is a low probability of having breast
cancer (even in the highest risk group). This low probability may
mean that the discriminatory power of a breast cancer risk model
won’t be as high as a risk model targeted to other common
diseases such as cardiovascular events, for instance. Another
potential limitation in the applicability in the screening context is
the completeness and the number of included risk factors, which
ranged from ﬁve to 18. Nevertheless, some potentially relevant
risk factors such as genetic markers have been only included in
few models. Recent studies43,44 have shown that adding genetic
information as a risk factor can increase the discriminative
accuracy of the different models which opens the line for further
evaluation. An evaluation that should ﬁrst assess the calibration of
these models in prospective cohort studies.
Overall, women are usually screened using mammography.
Particularly in Europe, most programmes invite women for
screening every 2 years.2 The presence of some mammographic
features in these screening mammograms may be related to the
risk of developing breast cancer, as has been recently pointed out
by some authors.21,45 Only one of the 24 models identiﬁed in this
systematic review included microcalciﬁcations and masses found
at mammography as risk factors in the model.21 Time-changing
variables such as radiological variables may not be as stable as
personal history. However, in a screening context, this information
is especially relevant because it is easily available from previous
screening examinations.
Quality of the evidence
We found variability in the design of the studies that were used to
obtain the cancer risk estimates. Notably, the study design used in
the BCSC model was a cohort, which is a robust epidemiology
design that allows developing and validating prediction models.
Another frequently used design was the case-control study,
nested or not. Contrary to the cohort study, time-changing
variables may not be well obtained in case-control studies.
Regarding the external validation, the models showed some lim-
itations given that few of them were further evaluated in different
contexts. As far as we know, there are numerous scientiﬁc
publications reporting external model validation in different
settings and countries. These studies may help to understand
the performance of a model in a speciﬁc context, but this issue
was out of the scope of our review and, therefore, we have not
included external validation studies. As an example of the
relevance of these studies, we can inform that the BCRAT model
has more than 50 articles informing the external validation of
these models in different countries.46 The Rosner-Colditz model
has also been validated in several studies, one of the most
complete validations being the one performed in 2013 by the
authors themselves.37 On the other hand, we found that although
the Eriksson et al.19 model reports the highest AUC (0.71), this
model has not been externally validated, which increases the
uncertainty about its applicability.
Also, there were limitations in data inputs, mostly due to the
fact that in several models the information was provided by self-
reported questionnaires that may affect the accuracy of the
results. Finally, there is a limitation when comparing the AUROC or
E/O ratio across the models given that there is great heterogeneity
amongst them. The models were targeted to different popula-
tions, included different sets of risk factors, and often used
different methodologies. We have taken into account all these
variations and presented the results by model categories.
Potential biases in the review process
This systematic review was limited to studies published in English
and did not involve an active search for grey literature, which is
literature that is not formally published in sources such as books
or journal articles. Therefore, some models may not have been
identiﬁed. However, since we have conducted a comprehensive
literature search in Medline, EMBASE and The Cochrane Library,
we estimate that the loss of information due to the study selection
criteria is low. Some key genetically oriented models, such as
BOADICEA47 and BRACAPRO48 were not included in this review
because they are aimed at high risk women and not useful for
women in the general population in the screening context. Full-
text screening and data abstraction process were performed by
two researchers, which increase the quality of the review process.
Moreover, as far as we know, this is the ﬁrst review assessing the
risk of bias of the identiﬁed risk prediction models.
CONCLUSIONS
The development of individualised breast cancer risk prediction
models has increased over the last three decades, but the
improvements in both the discriminatory power and calibration
accuracy are still limited. Despite the time that has passed since
the ﬁrst model was published and a large number of available
publications, only one model addressed to women attending a
population-based screening programme21 was identiﬁed. Cur-
rently, it is still a challenge to recommend any of the models as
the standard for predicting individual risk in screening context.
However, the models have been updated by adding new
variables, such as common genetic variation or radiologic
variables and have shown improvements in their quality as well
as in their discriminative accuracy. These new variables need
further evaluation to conﬁrm its promising impact in the
prediction capacity to propose personalised strategies for breast
cancer screening.
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